lunes, 20 de abril de 2020

An FDA tool for hastening approvals isn’t very useful for breast cancer drugs. (STAT)

The Readout
Damian Garde & Meghana Keshavan

More reads

  • An FDA tool for hastening approvals isn’t very useful for breast cancer drugs. (STAT)
  • British government enlists AstraZeneca, BIA for pandemic task force. (FierceBiotech)
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)